• Explore /
  • Poster
  • / Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).

Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).

Abstract Poster

Authors

null

Evaristo Maiello

U.O. Oncologia, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

Evaristo Maiello , Gabriele Di Maggio , Stefano Sergio Cordio , Saverio Cinieri , Francesco Giuliani Sr., Salvatore Pisconti , Antonio Rinaldi , Antonio Febbraro , Tiziana Pia Latiano , Michele Aieta , Daniele Rizzi , Massimo Di Maio , Giuseppe Colucci , Roberto Bordonaro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

2010-022091-31

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3542)

DOI

10.1200/JCO.2018.36.15_suppl.3542

Abstract #

3542

Poster Bd #

35

Abstract Disclosures

Similar Posters

First Author: Roberto Moretto

First Author: Christophe Tournigand

First Author: Keiichiro Ishibashi

First Author: Anthony Chan